Defence Therapeutics Granted CNRI-H from Canadian Nuclear Laboratories

Defence Therapeutics Inc., a Canadian biopharmaceutical company, has received approval from the Canadian Nuclear Laboratories (CNL) under their Canadian Nuclear Research Initiative Health (CNRI-H) Program. This approval will accelerate the company's radio-immuno-conjugates development program.

Defence Therapeutics will focus on producing and evaluating new variants of 111In-AccuTOX®-Trastuzumab. These constructs aim to avoid endosome entrapment and ensure nuclear localization, where 111In emits Auger Electrons to kill cancer cells. This project targets HER2-positive cancers for higher potency and improved therapeutic outcomes.

The CNRI-H project includes synthesizing and radiolabeling AccuTOX®-Trastuzumab, followed by in vitro and in vivo efficacy tests. The end goal is to identify the most biologically active molecule to treat tumors resistant to current HER2 therapies.

Sebastien Plouffe, CEO of Defence Therapeutics, highlighted the collaboration with CNL, emphasizing the strong scientific team and the project's potential to benefit cancer patients through advanced radio-immuno-conjugates.